Accelerating Development and Building Trust in COVID-19 Vaccines With Public Quality Standards


Along with speed and leveraging different strategies, including live attenuated viruses, viral vectors, proteins, and DNA or RNA vaccines, we need to ensure that new vaccines and treatments are trusted by healthcare providers and ultimately patients. Jaap Venema, Ph.D., USP Chief Science Officer, discusses how trust can be built to encourage patient adoption of new vaccines, particularly for COVID-19.